Oxaliplatine Hospira

Oxaliplatin, the active ingredient in Oxaliplatine Hospira, is an alkylating agent presented as an intravenous solution for intravenous use. It is employed in the treatment of colorectal cancer, including metastatic disease, and serves as adjuvant therapy for stage III colon cancer.

GNH USA supplies Oxaliplatine Hospira as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with sourcing from the European Union market and all batches meeting EU pharmacopoeial specifications to ensure product integrity.

Oxaliplatin is an alkylating antineoplastic agent used in colorectal cancer treatment pathways.

- Colorectal cancer: improves survival when combined with fluoropyrimidine‑based regimens. - Metastatic colorectal cancer: provides disease control in patients with advanced disease. - Adjuvant therapy for stage III colon cancer: reduces risk of recurrence after surgical resection. - Combination with 5‑FU/leucovorin: enhances cytotoxic effect compared with chemotherapy alone.

Oxaliplatin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Peripheral sensory neuropathy (tingling or numbness) - Fatigue or weakness - Diarrhea - Neutropenia or other reductions in blood cell counts - Mild electrolyte disturbances

Serious or Rare Side Effects: - Severe allergic or anaphylactic reactions - Acute neurotoxicity with motor dysfunction - Hepatic dysfunction or elevated liver enzymes - Tumor lysis syndrome in high‑burden disease - Severe myelosuppression leading to infection or bleeding

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for toxicity.

- Renal function: assess baseline creatinine and adjust infusion if impaired. - Hepatic function: monitor liver enzymes during treatment. - Peripheral neuropathy: evaluate before each cycle and discontinue if severe. - Myelosuppression: perform regular complete blood counts and manage neutropenia as needed. - Pregnancy and lactation: avoid use due to unknown safety; discuss risks with the prescriber. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Oxaliplatin can interact with other medicines, requiring attention to avoid increased toxicity or reduced efficacy.

Major Interactions (Avoid): - Concurrent use with other platinum agents (e.g., cisplatin) – may amplify nephrotoxicity and neurotoxicity. - High‑dose vitamin C supplementation – potential reduction in antitumor activity. - Live vaccines – heightened infection risk due to immunosuppression.

Moderate Interactions (Monitor Closely): - Antiemetics such as ondansetron – may improve tolerability without affecting efficacy. - Nephrotoxic drugs (e.g., aminoglycosides) – monitor renal function closely. - Radiation therapy to the abdomen – increased risk of peripheral neuropathy.